Session » (2124–2158) Pediatric Rheumatology – Clinical Poster III

Date: Tuesday, October 28, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 2155

A Novel TNFAIP3 Mutation Associated with Large Vessel Vasculitis: Expanding the Phenotypic Spectrum of A20 Haploinsufficiency

10:30AM-12:30PM: Abstract Number: 2152

Blau Syndrome: features beyond the classic triad and proposal for clinical criteria

10:30AM-12:30PM: Abstract Number: 2156

Bridging the Gap: Juvenile Spondyloarthritis (JSpA) vs. Chronic Non-Bacterial Osteomyelitis (CNO)

10:30AM-12:30PM: Abstract Number: 2127

Chronic Non-Bacterial Osteomyelitis of the Petrous Bone: A Case Series

10:30AM-12:30PM: Abstract Number: 2136

Confirming The Validity Of The New EULAR/ACR Classification Criteria For Pediatric Chronic Nonbacterial Osteomyelitis

10:30AM-12:30PM: Abstract Number: 2125

Development and Validation of Minimal Clinically Important Difference for Children with Chronic Nonbacterial Osteomyelitis Using a Consensus and Data-Driven Approach

10:30AM-12:30PM: Abstract Number: 2129

Distinct endotypes of SURF associated with clinical phenotypes, inflammatory cytokines, and treatment responses

10:30AM-12:30PM: Abstract Number: 2147

Elevated fMET and GDF-15 Circulating Levels in Pediatric CNO Patients with Psoriasis Define a Distinct Mitochondrial-Inflammatory Signature

10:30AM-12:30PM: Abstract Number: 2145

EOS® Imaging System Is a Novel, Rapid, Safe, and Effective Technique To Detect And Assess Calcinosis In JDM

10:30AM-12:30PM: Abstract Number: 2158

Evaluating Nailfold Capillary Changes as Indicators of Disease Activity in Juvenile Dermatomyositis

10:30AM-12:30PM: Abstract Number: 2133

Examination of HLA-DRB1*15-linked Candidate Antigens in Still’s Disease with and without Lung Disease and Features of Drug Hypersensitivity

10:30AM-12:30PM: Abstract Number: 2138

Factors driving therapeutic decision-making in Still’s Disease: When to Start and When to Stop? Data from the METAPHOR Project Worldwide Survey

10:30AM-12:30PM: Abstract Number: 2153

Giant Coronaries in Children with Kawasaki Disease: A Single Centre Experience

10:30AM-12:30PM: Abstract Number: 2140

Identification of immune phenotypes in systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD) using high parameter flow cytometry

10:30AM-12:30PM: Abstract Number: 2146

Impact of a Clinical Pathway on Medication Use and Outcomes in Kawasaki Disease

10:30AM-12:30PM: Abstract Number: 2148

Initial MRI Findings as Predictors of Disease Phenotype in Juvenile Dermatomyositis: A Comparative Study of Myositis Specific Antibodies NXP2-Positive and Myositis Specific Antibody-Negative Patients in a Large Tertiary Hospital

10:30AM-12:30PM: Abstract Number: 2134

Krebs von den Lungen-6 (KL-6) as a Potential Diagnostic Biomarker of Lung Disease in Pediatric Systemic Juvenile Idiopathic Arthritis: Preliminary Findings from a Multisite US Cohort

10:30AM-12:30PM: Abstract Number: 2135

Medication Use and Disease Activity in Systemic Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

10:30AM-12:30PM: Abstract Number: 2142

Multidisciplinary Rheumatology Transition Clinic for Young Adults Shows Improved Experience, Utilization, and Health Maintenance: A Mixed-Methods Evaluation

10:30AM-12:30PM: Abstract Number: 2157

Optimizing the Diagnosis and Treatment of Kawasaki Disease-Associated Macrophage Activation Syndrome: A Clinical Cohort and Literature Analysis

10:30AM-12:30PM: Abstract Number: 2126

Preliminary Results of a Large, Global Registry Characterizing Childhood-Onset Takayasu Arteritis

10:30AM-12:30PM: Abstract Number: 2128

Prevalence of Risks and Complications in a Longitudinal International Cohort of Children with Chronic Nonbacterial Osteomyelitis (CNO)

10:30AM-12:30PM: Abstract Number: 2139

Real-Life Treatment Strategies for Refractory Still’s Disease: Results from a Worldwide Survey, the METAPHOR Project

10:30AM-12:30PM: Abstract Number: 2151

Real-World Experience with IL-1 Blockade in Children with Undifferentiated Systemic Autoinflammatory Diseases (uSAIDs)

10:30AM-12:30PM: Abstract Number: 2124

Reliability and Validation of the Physician’s Global Assessment of Lung Disease (PGALD) in Systemic Juvenile Idiopathic Arthritis -Associated Lung Disease (SJIA-LD)

10:30AM-12:30PM: Abstract Number: 2150

Rheum to Grow:An Approach Towards Human Centered Design through a Qualitative Analysis on the Transition from Pediatric to Adult Rheumatology

10:30AM-12:30PM: Abstract Number: 2149

Rheumatology Transitions of Care: Patient Stability and Follow-Up at a Single Center

10:30AM-12:30PM: Abstract Number: 2143

Ruxolitinib for Refractory sJIA/AOSD: A Single Center Case Series

10:30AM-12:30PM: Abstract Number: 2130

Systemic juvenile idiopathic arthritis- Fifteen-year experience from a tertiary centre at Bristol, United Kingdom

10:30AM-12:30PM: Abstract Number: 2144

The Association Between Age at Diagnosis and Health-Related Quality of Life in ANCA-Associated Vasculitis

10:30AM-12:30PM: Abstract Number: 2132

The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-To-Adult Rheumatology Transition Program, Reduces Median Time between Final Pediatric, First Adult, and Second Adult Visits

10:30AM-12:30PM: Abstract Number: 2137

Therapeutic Strategies in Newly Diagnosed Still’s Disease: Real-Life Clinicians’ Choices from the METAPHOR Project Worldwide Survey

10:30AM-12:30PM: Abstract Number: 2131

Transition from Juvenile Dermatomyositis to Spondyloarthritis: A Novel Overlapping Inflammatory Phenotype

10:30AM-12:30PM: Abstract Number: 2141

Treatment of Refractory Still’s/Systemic Juvenile Idiopathic Arthritis Lung Disease with the bi-specific IL-1Beta/IL-18 neutralizing antibody MAS825

10:30AM-12:30PM: Abstract Number: 2154

Whole-Body MRI Findings in a Cohort of Children with Chronic Nonbacterial Osteomyelitis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].